Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEV-53408 in Participants With Vitiligo
NCT06625177Phase 1Recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Nov 2024
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of TEV-53408 in Vitiligo (3 cohorts), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Number of Participants With at Least One Treatment-Emergent Adverse Event, Number of Participants With at Least One Serious Treatment-Emergent Adverse Event and 3 more. Started Nov 2024; status: recruiting.
02
Drugs
TEV-53408
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT06625177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06625177.